{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:06Z","timestamp":1792708866605,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011913","name":"Kaohsiung Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jiph.2026.103385","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:10:35Z","timestamp":1792249835000},"page":"103385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIV resistance in patients with virological failure to single tablet regimen: Roles of second generation integrase strand transfer inhibitors (INSTIs)"],"prefix":"10.1016","volume":"19","author":[{"given":"Hung-Chin","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Tzu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2026.103385_bib1","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.jiph.2026.103385_bib2","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jiph.2026.103385_bib3","doi-asserted-by":"crossref","unstructured":"Blanco J.L., Montaner J.S., Marconi V.C., Santoro M.M., Campos-Loza A.E., Shafer R.W., et. al. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine\/lamivudine + efavirenz admin istered on a multiple tablet therapy. AIDS. 2014;28: 2531\u20132539. doi: 10.1097\/QAD.0000000000000424.","DOI":"10.1097\/QAD.0000000000000424"},{"key":"10.1016\/j.jiph.2026.103385_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170661","article-title":"Dat\u2019AIDS study group. Effectiveness and tolerance of single tablet versus once daily multiple tablet regimens as first-line antiretroviral therapy - Results from a large french multicenter cohort study","volume":"12","author":"Cotte","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jiph.2026.103385_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jmii.2024.11.003","article-title":"Forty years of HIV infection and AIDS in Taiwan: reflection on the past and looking toward the future","volume":"58","author":"Huang","year":"2025","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jiph.2026.103385_bib6","unstructured":"Taiwan Center for Diseases Control. https:\/\/www.cdc.gov.tw\/File\/Get\/p70Xg8MZBV1TU4M1eg17dg, access on 3 Feb 2025."},{"key":"10.1016\/j.jiph.2026.103385_bib7","volume":"16","author":"Liou","year":"2024"},{"key":"10.1016\/j.jiph.2026.103385_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2147\/IDR.S165811","article-title":"HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan","volume":"11","author":"Tsai","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2026.103385_bib9","doi-asserted-by":"crossref","first-page":"e717","DOI":"10.1016\/S2352-3018(22)00124-2","article-title":"HIV, chemsex, and the need for harm-reduction interventions to support gay, bisexual, and other men who have sex with men","volume":"9","author":"Strong","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiph.2026.103385_bib10","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.2147\/IDR.S273704","article-title":"Prevalence of HIV-1 integrase strand transfer inhibitor resistance in treatment-na\u00efve voluntary counselling and testing clients by population sequencing and illumina next-generation sequencing in Taiwan","volume":"13","author":"Tsai","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2026.103385_bib11","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. Available at https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed on 20 Jun 2026."},{"key":"10.1016\/j.jiph.2026.103385_bib12","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1469-0691.2010.03375.x","article-title":"Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption","volume":"17","author":"Canducci","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiph.2026.103385_bib13","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jiph.2026.103385_bib14","first-page":"457","article-title":"update of the drug resistance mutations in HIV-1","volume":"33","author":"Wensing","year":"2025","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jiph.2026.103385_bib15","unstructured":"Stanford University HIV Drug Resistance Datbase. Available from: https:\/\/hivdb.stanford.edu. Version 10.1, last update 2026-01-18. Accessed April 21, 2026."},{"key":"10.1016\/j.jiph.2026.103385_bib16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/JCMA.0000000000001152","article-title":"Prevalence of integrase strand transfer inhibitor resistance in people living with HIV and virological failure","volume":"87","author":"Tsai","year":"2024","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.jiph.2026.103385_bib17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment emergent dolutegravir resistance mutations in individuals na\u00efve to hiv-1 integrase inhibitors: a rapid scoping review","volume":"15","author":"Tao","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2026.103385_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/jac\/dkae377","article-title":"Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study","volume":"80","author":"Marcelin","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103385_bib19","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3390\/v14122591","article-title":"Different pathways conferring integrase strand-transfer inhibitors resistance","volume":"14","author":"Richetta","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jiph.2026.103385_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12981-020-0262-y","article-title":"HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study","volume":"17","author":"Orta-Resendiz","year":"2020","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jiph.2026.103385_bib21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/jac\/dkad101","article-title":"Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings","volume":"78","author":"Armenia","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiph.2026.103385_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","article-title":"et. al. Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice","volume":"30","author":"Armenia","year":"2022","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034126002571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:31:34Z","timestamp":1792708294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034126002571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1876034126002571"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103385","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV resistance in patients with virological failure to single tablet regimen: Roles of second generation integrase strand transfer inhibitors (INSTIs)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2026.103385","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"103385"}}